跳转至内容
Merck
CN

E7906

艾美拉唑镁抗溃疡病药 镁盐 水合物

≥98% (HPLC), proton pump inhibitor, powder

别名:

(S)-奥美拉唑镁, (T-4)-双[6-甲氧基-2-[(S)-[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基-κO]-1H-苯并咪唑基-κN3]-镁 水合物, 埃索美拉唑镁三水合物

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C34H36MgN6O6S2 · xH2O
化学文摘社编号:
分子量:
713.12 (anhydrous basis)
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

艾美拉唑镁抗溃疡病药 镁盐 水合物, ≥98% (HPLC)

SMILES string

O.COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)S(=O)Cc5ncc(C)c(OC)c5C)c(nc2c1)S(=O)Cc6ncc(C)c(OC)c6C

InChI

1S/2C17H18N3O3S.Mg.H2O/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;;/h2*5-8H,9H2,1-4H3;;1H2/q2*-1;+2;/t2*24-;;/m00../s1

InChI key

LGRFYKXKCZKDLS-DIYDTZFBSA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -128 to -146°, c = 0.5 in methanol

color

white to off-white

solubility

DMSO: ≥5 mg/mL

originator

AstraZeneca

storage temp.

2-8°C

Quality Level

Application

埃索美拉唑镁水合物已被用于以不依赖ATP12A的方式诱导细胞内酸化。

Biochem/physiol Actions

埃索美拉唑镁二水合物是一种领先的质子泵抑制剂。

Features and Benefits

该化合物由阿斯利康开发。要浏览其他药物开发化合物和批准的药物/候选药物列表,单击此处

General description

埃索美拉唑是奥美拉唑的(S)异构体。它可阻断H+/K+-ATPase并降低胃壁细胞释放盐酸的水平。埃索美拉唑可用于治疗胃食管反流病(GERD)。

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Yukiko Nakagawa et al.
Biological & pharmaceutical bulletin, 43(4), 682-687 (2020-04-03)
We previously showed that adhesive aggregates were formed when levofloxacin hydrate tablets and lansoprazole orally disintegrating (OD) tablets were suspended in water in the clinical context. In this study, we have clarified the factors causing aggregate formation, focusing on the
Esomeprazole
Scott LJ, et al.
Drugs, 62(10), 1503-1538 (2002)
A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD)
Kalaitzakis E and Bjornsson E
Therapeutics and Clinical Risk Management, 3(4), 653-653 (2007)
Mitsuhiro Nishihara
European journal of drug metabolism and pharmacokinetics, 44(5), 713-717 (2019-04-18)
A recent report indicated that the pharmacodynamic interaction between clopidogrel and vonoprazan leading to attenuation of the anti-platelet effect of clopidogrel was unlikely to be caused by the inhibition of cytochrome P450 (CYP) 2B6, CYP2C19, or CYP3A4/5 by vonoprazan, based
Susan M Watanabe et al.
Scientific reports, 10(1), 4003-4003 (2020-03-07)
Two proton pump inhibitors, tenatoprazole and esomeprazole, were previously shown to inhibit HIV-1 egress by blocking the interaction between Tsg101, a member of the ESCRT-I complex, and ubiquitin. Here, we deepen our understanding of prazole budding inhibition by studying a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持